Effect Of Rosuvastatin Combined With Ezetimibe On Serum Hs-CRP,ET-1,Lp-PLA2 And Neurological Function In Patients With Acute Cerebral Infarction

Objective: By comparing the effects of rosuvastatin combined with ezetimibe on serum high sensitivity C-reactive protein（Hs-CRP）,endothelin-1（ET-1）,lipids Protein-related phospholipase A2（Lp-PLA₂）and neurological function in patients with acute cerebral infarction,to explore the optimal combination doses of lipid-lowering drugs.Method:Collect 79 cases of the patients with atherosclerotic cerebral infarction treated by Department of Neurology,Second Hospital of Hebei Medical University on January 2016 to October 2016.There were 53 males and 26 females with age range of 41-80 years old.The patients were randomly divided into low dose rosuvastatin group（10mg/d,n=20）,low dose combined group（rosuvastatin 10mg/d + ezetimibe 10mg/d,n=20）,high dose rosuvastatin group（20mg/d,n=19）,high dose combination group（rosuvastatin 20mg/d + ezetimibe 10mg/d,n=20）.10 days for a course of treatment.The levels of serum Hs-CRP,ET-1,Lp-PLA₂,cholesterol（CHOL）,triglyceride（TG）,Low density lipoprotein（LDL）,high density lipoprotein（HDL）and National Institutes of Health Stroke Scale（NIHSS）were measured on the first day and the 10 th day of hospitalization.Serum ET-1 was measured by enzyme linked immuno-sorbent assay（ELISA）kit,while serum Hs-CRP,Lp-PLA₂,CHOL,TG,LDL,HDL were determined by the Second Hospital of Hebei Medical University Laboratory.SPSS 21.0 statistical software was used for statistical analysis.Results:1 There were no significant differences in age,sex ratio,BMI,Hcy level and uric acid level among the four groups（P> 0.05）,the past medical history on hypertension,diabetes,acute coronary disease and past stroke are consistent with the result above（P>0.05）.The bad behavior referred to drinking and smoking are consistent with the result above（P>0.05）,The serum levels of ET-1,Hs-CRP,Lp-PLA₂,CHOL,TG,LDL and HDL in the four groups were not significantly different between the four groups（P> 0.05）.2 After treatment,the levels of serum ET-1 were significantly decreased among low-dose combination group,high-dose group,high-dose combination group,but there’s no significance statistically between them（P = 0.199,P> 0.05）,there was a positive correlation between the level of serum ET-1 with the level of LDL（P = 0.001,P <0.01）after treatment.3 After treatment,the change of Serum Hs-CRP levels was not clear,there was no significant difference between the four groups.4 The plasma Lp-PLA₂ level was lower than before after treatment,but with no significant differences（P> 0.05）.5 The serum CHOL levels were statistically significant lower than before after treatment（P <0.05）.There was significant difference between the high rosuvastatin dose groups and the low rosuvastatin dose groups（P <0.05）.6 The serum TG levels were significantly lower than before treatment,but there was no significant difference between the four groups（P = 0.105,P> 0.05）.7 The level of serum LDL decreased after treatment,and the difference was statistically different between the four groups after treatment（P=0.000,P <0.05）.There was significant difference between the high rosuvastatin dose groups and the low rosuvastatin dose groups respectively（P <0.05）.8 The serum HDL level was higher than before after treatment,but with no significant differences（P> 0.05）.9 There was no significant difference in the utility rate and excellence rate of clinical efficacy between the four groups after treatment（P=0.932,P=0.974,P>0.05）.Conclusion:1 High-dose rosuvastatin（20mg/d）decreased CHOL levels and LDL level were more significantly than low-dose rosuvastatin（10mg/d）combined with ezetimibe（10mg/d）.2 Risuvastatin combined with ezetimibe can improve the endothelial function,which is probably related with its influence on serum LDL levels.3 The role of risuvastatin combined with ezetimibe on serum Hs-CRP,Lp-PLA₂ and neurological function is not accurate.